Cargando…
Identification of a Cardiac Glycoside Exhibiting Favorable Brain Bioavailability and Potency for Reducing Levels of the Cellular Prion Protein
Several strands of investigation have established that a reduction in the levels of the cellular prion protein (PrP(C)) is a promising avenue for the treatment of prion diseases. We recently described an indirect approach for reducing PrP(C) levels that targets Na,K-ATPases (NKAs) with cardiac glyco...
Autores principales: | Eid, Shehab, Zerbes, Thomas, Williams, Declan, Wang, Xinzhu, Sackmann, Chris, Meier, Sammy, Dulin, Nickolai O., Nagorny, Pavel, Schmitt-Ulms, Gerold |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9736291/ https://www.ncbi.nlm.nih.gov/pubmed/36499150 http://dx.doi.org/10.3390/ijms232314823 |
Ejemplares similares
-
Cardiac glycoside-mediated turnover of Na, K-ATPases as a rational approach to reducing cell surface levels of the cellular prion protein
por: Mehrabian, Mohadeseh, et al.
Publicado: (2022) -
The cellular prion protein interacts with and promotes the activity of Na,K-ATPases
por: Williams, Declan, et al.
Publicado: (2021) -
NCAM1 Polysialylation: The Prion Protein's Elusive Reason for Being?
por: Mehrabian, Mohadeseh, et al.
Publicado: (2016) -
Somatostatin slows Aβ plaque deposition in aged APP(NL-F/NL-F) mice by blocking Aβ aggregation
por: Williams, Declan, et al.
Publicado: (2023) -
PrionHome: A Database of Prions and Other Sequences Relevant to Prion Phenomena
por: Harbi, Djamel, et al.
Publicado: (2012)